The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: No interaction with the response to pravastatin therapy and no effects on cardiovascular outcome - A prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy

Journal of the American College of Cardiology

Volumn 43, Issue 5, 2004, Pages 854-857

  De Grooth, Greetje J ^a   Zerba, Kim E ^b   Huang, Shu Pang ^b   Tsuchihashi, Zenta ^b   Kirchgessner, Todd ^b   Belder, René ^b   Vishnupad, Priya ^b   Hu, Beihong ^b   Klerkx, Anke H E M ^a   Zwinderman, Aeilko H ^a   Jukema, J Wouter ^c   Sacks, Frank M ^d   Kastelein, John J P ^a,e   Kuivenhoven, Jan Albert ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b BRISTOL MYERS SQUIBB   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

CARE; CETP; CHD; Cholesterol And Recurrent Events study; Cholesteryl ester transfer protein; Coronary heart disease; HDL c; High density lipoprotein cholesterol; LDL c; Low density lipoprotein cholesterol; MI; Myocardial infarction

Indexed keywords

CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR FUNCTION; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DEATH; DRUG EFFECT; FATALITY; GENETIC POLYMORPHISM; GENOTYPE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; CORONARY ARTERIOSCLEROSIS; FEMALE; GLYCOPROTEINS; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PRAVASTATIN; PROSPECTIVE STUDIES; RECURRENCE; SITE-SPECIFIC DNA-METHYLTRANSFERASE (ADENINE-SPECIFIC); TIME FACTORS; TREATMENT OUTCOME;

EID: 10744219782     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2003.08.056     Document Type: Article

References (7)

1. Kuivenhoven J.A., Jukema J.W., Zwinderman A.H., et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med. 338:1998;86-93.
2. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 335:1996;1001-1009.
3. Brousseau M.E., O'Connor J.J. Jr, Ordovas J.M., et al. Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency Veterans affairs hdl cholesterol intervention trial. Arterioscler Thromb Vasc Biol. 22:2002;1148-1154.
4. Ordovas J.M., Cupples L.A., Corella D., et al. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk The framingham study. Arterioscler Thromb Vasc Biol. 20:2000;1323-1329.
5. Liu S., Schmitz C., Stampfer M.J., et al. A prospective study of TaqIB polymorphism in the gene coding for cholesteryl ester transfer protein and risk of myocardial infarction in middle-aged men. Atherosclerosis. 161:2002;469-474.
6. Nikiforov TT, Rendle RB, Goelet P, et al. Genetic Bit Analysis: a solid phase method for typing single nucleotide polymorphisms. Nucleic Acids Res 1994;22:4167-75.
7. SAS Institute, Inc. SAS/STAT User's Guide, Version 8, Cary NC: SAS Institute, Inc., 1999.